Supplemental Figure 1. Disposition of subjects.

Locations of Clinical Sites: Harmonex Neuroscience Research, Dothan, AL 36303, USA; Neuropsychiatric Research Center of Orange County, Orange, CA 92868, USA; Indago Research & Health Center, Inc., Hialeah, FL 33012, USA; Clinical Neuroscience Solutions, Inc., Jacksonville, FL 32217, USA; Miami Clinical Research, Miami, FL 33155, USA; Advanced Clinical Research, Meridian, ID 83642, USA; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Finger Lakes Clinical Research, Rochester, NY 14618, USA; Clinical Neuroscience Solutions, Inc., Memphis, TN 38119, USA; Texas Physicians Medical Research Group, Arlington, TX 76014, USA; Houston Clinical Trials, Houston, TX 77098, USA; Family Psychiatry of the Woodlands, The Woodlands, TX 77381, USA.

Institutional Review Board (IRB): Advarra IRB, 6940 Columbia Gateway Drive, Suite 110, Columbia, MD 21046, USA. This was a central IRB used by all sites, except Icahn School of Medicine at Mount Sinai, which used a local IRB: Program for the Protection of Human Subjects, IRB, Mount Sinai Health System, One Gustave L. Levy Place, Box 1081 New York, NY 10029, USA.

Abbreviations: VLX-ER, viloxazine extended-release.

*Number of subjects in the safety population (assigned treatment) is used as denominator for this section.